TNF and lymphoma: One review of 18 randomized trials involving 8800 patients, found no increase in the odds of death, serious adverse events, serious infection, lymphoma, non-melanoma skin cancers or the composite endpoint of non-cutaneous cancers plus melanomas with recommended doses of TNF-alpha blocking agents when evaluated using the unadjusted meta-analytic method [67].